EPO vs YK-11
A side-by-side research comparison of EPO and YK-11 across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | EPO | YK-11 |
|---|---|---|
| Full name | Erythropoietin (EPO) | YK-11 (Myostatin Inhibitor / SARM) |
| Category | Muscle Growth | Muscle Growth |
| Status | FDA-approved drug (prescription) | Research compound |
| Mechanism | Binds erythropoietin receptors on bone marrow progenitor cells, stimulating proliferation and maturation of red blood cells. More red cells raise oxygen-carrying capacity, but also thicken the blood. | Partial androgen receptor agonist that induces follistatin expression, creating dual myostatin inhibition and AR activation. |
| Molecular weight | ~34 kDa (glycosylated) | 430.54 Da |
| Half-life | ~4-13 hours (varies by formulation) | ~6-10 hours |
| Bioavailability | Subcutaneous or intravenous injection | ~70% oral |
| Typical dose | Prescription-only, condition-specific | 5-10 mg |
| Frequency | Per medical protocol | Once daily |
| Route | Subcutaneous or IV injection | Oral |
EPO reported benefits
- Increases red blood cell production
- Treats anemia (medical use)
- Raises oxygen-carrying capacity
YK-11 reported benefits
- Dual anabolic mechanism
- Follistatin induction
- Oral convenience
- Muscle hardening
Related comparisons
Research and educational reference only. Not medical advice.